11: MAJOR SALIVARY GLAND TUMORS
Adam Ferro, MD, MS
Ana Kiess, MD, PhD
H&P including complete head and neck exam and cranial nerve exam
Imaging—contrast-enhanced CT and MRI of neck
Fine-needle aspiration (FNA) of primary tumor
Dental and nutrition evaluations prior to radiation
PET/CT or CT chest
MRI of skull base if concern for perineural spread
Benign |
Surgery. Consider adjuvant RT for recurrent multifocal pleomorphic adenoma. |
cT1–T4a |
Surgery → adjuvant treatment as indicated (see “Post-op” section) |
Post-op pT1–T2 |
Consider adjuvant RT for int/high grade, adenoid cystic histology, tumor spillage, or perineural invasion (PNI) |
Post-op pT3–T4 |
Adjuvant RT for int/high grade, adenoid cystic histology, close/positive margins, PNI, nodal metastases, or LVI OR consider adjuvant chemoRT for positive margins or ECE |
Gross residual disease T4b Unresectable Unfit for surgery |
Definitive RT OR chemoRT OR palliation with chemo or RT OR supportive care |
M1 |
Palliation with chemo, RT, or surgery OR supportive care |
Simulate supine with neck extended, immobilize with thermoplastic mask. Consider mouthpiece. Wire scars. Consider bolus for disease near skin. Intravenous (IV) contrast if no contraindications. Fuse pre-op imaging.
High-risk areas: 66 Gy in 30 to 33 fx or 70 Gy in 35 fx
Intermediate-risk areas: 60 Gy in 30 fx, or 63 Gy in 35 fx
Low-risk areas: 54 Gy in 30 fx, or 56 Gy in 35 fx
High-risk areas: 63 Gy in 30 fx or 66 Gy in 33 fx
Intermediate-risk areas: 60 Gy in 30 fx
Low-risk areas: 54 Gy in 30 fx
High-risk areas: 70 Gy in 35 fx
Intermediate-risk areas: 63 Gy in 35 fx
Low-risk areas: 56 Gy in 35 fx
GTV = gross disease based on exam and imaging
Clinical target volume (CTV) high risk = GTV + margin for subclinical disease (5–10 mm)
CTV intermediate risk:
Parotid: entire parotid, facial nerve track if PNI, or adenoid cystic carcinoma
Submandibular: entire submandibular, lingual or hypoglossal nerve track if PNI, or adenoid cystic carcinoma
Neck: ipsilateral IB-V if node involvement
CTV low risk = ipsilateral IB-III if node negative (may omit neck in adenoid cystic or low-grade histologies)
PTV = CTV + 3- to 5-mm margin, depending on image guidance
CTV high risk = areas of positive margins or ECE
CTV intermediate risk:
Parotid: entire parotid bed, facial nerve track if PNI, or adenoid cystic carcinoma
Submandibular: entire submandibular bed, lingual or hypoglossal nerve track if PNI, or adenoid cystic carcinoma
Neck: ipsilateral IB-V if node involvement
Post-op areas
CTV low risk = ipsilateral IB-III if node negative (may omit neck in ACC or low-grade histologies)
PTV = CTV + 3- to 5-mm margin, depending on image guidance
6-MV photons
Intensity-modulated radiation therapy (IMRT) preferred, with image guidance if available
Prefer starting post-op cases within 6-weeks postsurgery
Posttreatment baseline imaging of head and neck within 6 months after adjuvant RT. If asymptomatic, H&P every 1 to 3 months for year 1, every 2 to 6 months for year 2, every 4 to 8 months for years 3 to 5, then annually. Thyroid screening every 6 to 12 months. Management of nutrition, dental, speech, swallow, hearing, and smoking cessation as indicated. Chest imaging as indicated for smoking history.
Retrospective study of 207 patients with major salivary carcinomas treated with surgery without post-op radiotherapy. Five- and 10-year local/regional control were 86% and 74%, respectively. Independent predictors of local/regional recurrence were pathologic lymph node metastasis, high grade, positive margins, and T3 to 4 disease. The presence of one negative prognostic factor decreased LRR control to 37% to 63% at 10 years.
Retrospective analysis of 498 patients treated with surgery and post-op RT or surgery alone. Post-op RT improved 10-year LC for patients with T3 to 4 tumors (84% vs. 18%), close margins (95% vs. 55%), incomplete resection (82% vs. 44%), bone invasion (86% vs. 54%), and perineural invasion (88% vs. 60%).
Retrospective analysis of 251 patients with cN0 salivary gland carcinoma treated with surgery and adjuvant RT. 131 patients (52%) received elective nodal irradiation. Elective nodal irradiation reduced the 10-year nodal failure rate from 26% to 0%. No nodal failures in patients with adenoid cystic or acinic cell histology.
Retrospective study of 101 patients with adenoid cystic carcinoma treated with RT ± surgery. The combined modality arm resulted in improved LC at 10-years (91% vs. 43%) and overall survival (OS) at 10 years (55% vs. 42%).
Retrospective study of 140 patients with adenoid cystic carcinoma treated with surgery ± RT. T4 disease, perineural invasion, omission of post-op radiation, and major nerve involvement were independent predictors of LR. Among patients treated with surgery and post-op radiation, dose lower than 60 Gy, T4 disease, and major nerve involvement were predictors of LR.